These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Overview of the pharmacokinetics of fluvoxamine. van Harten J. Clin Pharmacokinet; 1995 Oct; 29 Suppl 1():1-9. PubMed ID: 8846617 [Abstract] [Full Text] [Related]
7. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. Abernethy DR, Barbey JT, Franc J, Brown KS, Feirrera I, Ford N, Salazar DE. Clin Pharmacol Ther; 2001 Mar; 69(3):96-103. PubMed ID: 11240972 [Abstract] [Full Text] [Related]
8. Nefazodone pharmacokinetics: assessment of nonlinearity, intra-subject variability and time to attain steady-state plasma concentrations after dose escalation and de-escalation. Barbhaiya RH, Shukla UA, Chaikin P, Greene DS, Marathe PH. Eur J Clin Pharmacol; 1996 Mar; 50(1-2):101-7. PubMed ID: 8739819 [Abstract] [Full Text] [Related]
9. The safety profile of nefazodone. Robinson DS, Roberts DL, Smith JM, Stringfellow JC, Kaplita SB, Seminara JA, Marcus RN. J Clin Psychiatry; 1996 Mar; 57 Suppl 2():31-8. PubMed ID: 8626361 [Abstract] [Full Text] [Related]
13. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Davis R, Whittington R, Bryson HM. Drugs; 1997 Apr; 53(4):608-36. PubMed ID: 9098663 [Abstract] [Full Text] [Related]
14. Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study. Barbhaiya RH, Marathe PH, Greene DS, Mayol RF, Shukla UA, Gammans RR, Pittman KA, Robinson D. J Clin Pharmacol; 1995 Oct; 35(10):974-84. PubMed ID: 8568015 [Abstract] [Full Text] [Related]
15. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Perucca E, Cloyd J, Critchley D, Fuseau E. Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564 [Abstract] [Full Text] [Related]
16. Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment. Kroboth PD, Folan MM, Lush RM, Chaikin PC, Shukla UA, Barbhaiya R, Salazar DE. J Clin Psychopharmacol; 1995 Oct; 15(5):306-19. PubMed ID: 8830061 [Abstract] [Full Text] [Related]
17. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Barbhaiya RH, Shukla UA, Greene DS. Eur J Clin Pharmacol; 1995 Oct; 49(3):221-8. PubMed ID: 8665999 [Abstract] [Full Text] [Related]
19. Nefazodone in major depression: adjunctive benzodiazepine therapy and tolerability. Rickels K, Schweizer E, Case WG, DeMartinis N, Greenblatt DJ, Mandos LA, Garcia España FG. J Clin Psychopharmacol; 1998 Apr; 18(2):145-53. PubMed ID: 9580369 [Abstract] [Full Text] [Related]
20. Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects. Laroudie C, Salazar DE, Cosson JP, Cheuvart B, Istin B, Girault J, Ingrand I, Decourt JP. Eur J Clin Pharmacol; 1999 Feb; 54(12):923-8. PubMed ID: 10192752 [Abstract] [Full Text] [Related] Page: [Next] [New Search]